The number of risk sharing arrangements between pharmaceutical companies, regional and national governments has been growing in recent years as authorities strive to enhance efficiency given the uncertainty of outcomes and appreciable resource implications with many new drugs. These arrangements are just being considered in Brazil. OBJECTIVES: Analyse risk sharing arrangements in other countries including concerns to develop a basis for future activities in Brazil. METHODS: Joint activities are planned including (a) literature search of published papers in Europe, US, and Australia using key words including  risk sharing, coverage with evidence,price volume agreements, value-based pricing, pharmaceuticals, no cure no pay, pay back schemes, health impact guaranteeto document existing schemes and definitions including concerns, (b) an assessment of the potential legal approaches in Brazil (if different to other countries), (c) an assessment of the potential implications of such agreements to Brazilian public health/ Ministry of Health acknowledging growing resource pressures and the need to fund new products approved by the Ministry.  RESULTS: The initial research uncovered potential definitions as well as an appreciable number of risk sharing arrangements in operation across Canada, US, Europe and Australia. These are currently being reviewed for applicability to Brazil. The findings will be discussed in more detail during the presentation as the search progresses. CONCLUSIONS: There is an appreciable number of risk sharing arrangements globally. However, there is confusion regarding their terminology, legal status, administration costs, benefits andransparency. These issues will be discussed in relation to Brazil to help stimulate the debate among Latin American countries and whether they should develop such schemes.